Get informed when a big investor buys or sells
+ FollowOvervalued by 83.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $13.90 Million |
|---|---|
| Enterprise Value | $16.80 Million |
| Earnings per Share | $-0.02 |
| Beta | -0.68 |
| Outstanding Shares | 173,307,525 |
| P/E Ratio | -4.19 |
|---|---|
| PEG | 24.49 |
| Price to Sales | - |
| Price to Book Ratio | -0.08 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.22 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | -0.97 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who...